Atezolizumab Phase 3 Trial for Pleural Mesothelioma

People with mesothelioma treated with immunotherapy regimens like nivolumab (Opdivo) plus ipilimumab (Yervoy) have a median survival of 18.1 months, based on the phase 3 CheckMate 743 trial. In the KEYNOTE-483 trial, pembrolizumab (Keytruda) combined with chemotherapy yielded a median survival of 17.3 months, compared to 16.1 months with chemotherapy alone. Overall, FDA-approved immunotherapies extend median life expectancy to 17-18 months for people with unresectable pleural mesothelioma across stages. Survival varies by factors like cell type and treatment sequence, with 1-year rates around 68% and 2-year rates at 41% for Opdivo plus Yervoy.

Asbestos exposure causes mesothelioma, lung cancer, laryngeal cancer, and ovarian cancer. Mesothelioma accounts for more than 80% of cases linked to asbestos, while about 4% of lung cancer cases and a 40% increased risk of laryngeal cancer stem from exposure. Evidence also shows positive associations with pharyngeal, stomach, and colorectal cancers, though causation is less definitively established. Ongoing research by IARC explores these links further.

Immunotherapy combinations like nivolumab plus ipilimumab (Opdivo + Yervoy) show median overall survival of 18.1 months for people with mesothelioma, compared to 14.1 months with chemotherapy alone. One-year survival reaches 68%, two-year survival 41%, and three-year survival 23-25% in clinical trials. Five-year survival is 14% with immunotherapy versus 6% with chemotherapy overall, and higher (12-14%) for epithelioid or non-epithelioid subtypes. A meta-analysis of seven randomized trials confirms immunotherapy improves survival across lines of therapy and histologic subtypes.

No cure exists for mesothelioma, the cancer caused by asbestos exposure. Evidence shows 1-year survival rates of 79.6% for people with pleural mesothelioma receiving multimodal treatment, with 11% of surveyed individuals achieving remission through chemotherapy, surgery, or immunotherapy. The NERO trial demonstrated niraparib, a PARP inhibitor, reduced progression or death risk by 27% and delayed worsening by 1.5 months on average in recurrent cases. Ongoing research explores preventive agents like sulforaphane and therapies such as tumor treating fields, which extend survival by 4-6 months with chemotherapy. Standard options include surgery, radiation, chemotherapy, immunotherapy (nivolumab plus ipilimumab), and targeted therapy.

Immunotherapy duration for people with advanced non-small cell lung cancer (NSCLC) or pleural mesothelioma typically lasts up to 2 years in clinical trials and practice, after which treatment often stops if there is no disease progression. Studies show similar 4-year overall survival rates of 79-81% between fixed 2-year duration and indefinite continuation in NSCLC. For consolidation after chemoradiotherapy, 1-2 years is common, with durable responses observed post-treatment. Optimal duration remains under investigation, varying by regimen and response.

Immunotherapy shows highest efficacy in melanoma, where combination checkpoint inhibitors achieved about 50% 10-year survival in people with advanced disease. In cancers with mismatch repair deficient (dMMR or MMRd) mutations, such as certain rectal, colon, gastric, and esophageal tumors, nearly 80% of participants in a trial of 103 people responded to immunotherapy alone, with 100% success in rectal cases. Lung cancer and Hodgkin lymphoma also demonstrate response rates of 20-50% in select groups. Effectiveness varies by tumor type and genetics, with ongoing trials refining applications.

Immunotherapy has significantly improved survival outcomes for people with stage 4 cancer, particularly in melanoma, non-small cell lung cancer, and certain colorectal cancers. However, “cure” remains rare. For example, people with advanced non-small cell lung cancer and high PD-L1 expression achieve a 5-year overall survival rate of 31.9% with immunotherapy versus 15.5% with chemotherapy alone. In colorectal cancer with microsatellite instability-high tumors, 60-70% of people respond to immunotherapy. While some people with stage 4 disease have achieved remission or disease-free status, immunotherapy functions primarily as a long-term disease management strategy rather than a cure for most cancer types. Treatment eligibility depends on tumor characteristics, genetic markers, and protein expression, making individual outcomes highly variable.

Immunotherapy response is measured primarily through imaging scans that show tumor shrinkage or stabilization of tumor growth. Healthcare providers also monitor blood biomarkers such as circulating tumor DNA (ctDNA) levels, tumor markers (PSA, CEA, LDH), and immune-related blood counts, though no blood tests are currently FDA-approved to measure how well immunotherapy is working over time. Symptom improvement, such as reduced pain, fatigue, or shortness of breath, can indicate a therapeutic effect. It is important to note that side effects like inflammation do not reliably predict treatment success; many people with mesothelioma who respond well to immunotherapy experience few or no side effects. Results typically emerge gradually over weeks to months rather than immediately, as the immune system requires time to recognize and attack cancer cells.